AzTrials
AzTrials

Diabetic FootDFUNCT02577900

Diabetic Foot Ulcer Study on Topical Interventions

A study testing Acticoat absorbent, Honey gel sheet and Jelonet in people with Diabetic Foot, run by Queen Elizabeth Hospital, Hong Kong.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether nanocrystalline silver dressing, manuka honey dressing and conventional dressing are effective in the treatment of diabetic foot ulcer. Read more about this study

Who is it for?
Ages 40 to 85 years
Conditions the study is for
Diabetic Foot
What is being tested?
Acticoat absorbent, Honey gel sheet and Jelonet
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
31 participants
Where
No sites listed yet
Study dates
Feb 2013to Aug 2015
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • History of type 2 diabetes mellitus and
  • Age 40 or above with foot ulcer and
  • Ulcer with size equals or larger than 1 cm in diameter and
  • Ulcer located at or below malleolar region of foot and
  • Superficial ulcer, ulcer penetrates to tendon or capsule and
  • Ulcer without infection, mild and moderate infection and
  • Subject with no foreseeable surgery within 12-week study period

Who cannot join

  • HbA1c level ≥ 10% or
  • Severe ischemia with ankle-brachial index (ABI) ≤ 0.4 or
  • Ulcer deep into bone and joint or
  • Osteomyelitis or
  • Severe ulcer infection or
  • Known allergy to manuka honey/ nanocrystalline silver or
Show all 12Show fewer
  • Known case of venous ulcer or varicose vein or
  • Known case of benign or malignant tumor or
  • Known to have any auto-immune disease or
  • A condition requiring medication that affects the immune response or
  • Participation in other experimental treatment studies or
  • Pregnancy

About this study

Official title: Randomized, Controlled Study of Nanocrystalline Silver, Manuka Honey and Conventional Dressing in Healing Diabetic Foot Ulcer

The purpose of this study is to determine whether nanocrystalline silver dressing, manuka honey dressing and conventional dressing are effective in the treatment of diabetic foot ulcer.

Read the detailed description

Patient flow The target subjects were screened in the orthopedic department of two regional hospitals and one general outpatient clinic (GOPD). Those eligible potential subjects were recruited after they discharged from hospital according to the selection criteria. All the subjects were referred and intervened in an orthopedic nurse clinic a regional hospital. The subjects were randomized into three groups through a fixed block of 10 by online software. A sequence of assignment was generated and put into a sealed envelope by a research assistant. The investigator did not involve in randomization process and allocation sequence. The subjects were enrolled and allocated to different treatment arms according to the allocation sequence.

Data collection Outcome assessor blinding was employed in this study. A research assistant was responsible for measuring the wound size and taking clinical photo. In every clinical visit, the research assistant waited outside the clinic until the removal and proper cleansing of the wound by the first author so that she unaware of the topical treatment option. The subjects would be discontinued follow up when the wound was completely healed or till the end of 12-week study period.

Intervention All participants attended the nurse clinic for follow-up by the first author (nurse consultant) weekly in the first four week and then biweekly till 12 weeks of follow up period. They were nine clinical attendances totally. At each visit, sharp debridement for the non-viable tissue and stimulation of the vascularity on the avascular tissue were performed if needed by the first author. Then, he applied the topical dressing according to randomization sequence.

Statistical analysis All the analysis will be carried out according to the intention-to-treat principle. SPSS Statistics for Mac version 22 (SPSS Inc, Chicago, Illinois) was used for data analysis. Comparison would be made among groups by Fisher's exact test for nominal data and Kruskal-Wallis test for ordinal and scale data. The complete ulcer healing was compared among groups by Kaplan-Meier estimates. General estimating equation (GEE) was used to compare the ulcer size reduction rate, the wound fluid concentration of matrix metalloproteinase -9 (MMP9), tumor necrosis factor alpha (TNF-α) and interleukin-1 alpha (IL-1α) among groups. Statistical significance was set at p < 0.05 for all tests.

Sample size calculation

  • The probability of non-healing (p1) on nanocrystalline silver (nAg) group = 0.20
  • The probability (p2) of non-healing on manuka honey (MH)/conventional group = 0.50
  • The alpha (α) value was 0.05 and power (1-β) was 0.8
  • Ratio of sample size per group was 1:1
  • Therefore, the total sample subjects for 2 groups were 77. Each group needed 39 subjects. For 3 groups, the total numbers of subjects were 117.
  • From the experience, 10% of patients were loss to follow up. The actual numbers of subjects needs were 129. i.e. 43 subjects per group.

Data quality assurance In order to ensure the data quality, a research assistant was assigned to verify the source document and other trial records were accurate, complete, kept up-to-date and maintained. The student investigator trained the research assistant in the data quality assurance process. The student investigator also checked the data entry sheet with raw data every month. The responsibilities of research assistant were listed as follows.

  • Check the accuracy and completeness on the case screening form and consent form.
  • Verify the laboratory data in the case record form (CRF) were consistent with the corresponding laboratory result.
  • Verify the inter-current illness was reported on the CRF.
  • Verify all withdrawals and dropouts of enrolled subjects from this trial were reported and explained on the CRF.

If there was any missing data or data inconsistency, the research assistant was clarified the data with the internal electronic record of the hospital.

Handling of missing data The nature of this study was the multiple observations of subjects in regular censored points. Thus, the missing clinical data was handled by the last observation carried forward. For those laboratory data, statistical method of general estimating equation was used for the analysis on the repeated measures among groups. The missing data was under the missing completely at random (MCAR) assumption. Therefore, the laboratory missing data did not need to make estimation in the present study.

Conditions
Diabetic Foot
Being tested
Acticoat absorbent, Honey gel sheet, Jelonet
Keywords
foot ulcer and honey and silver
Medical subject headings
Diabetic Foot, Foot Ulcer

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Acticoat absorbentDevice

    Also called nanocrystalline silver alginate

    Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval

  • Honey gel sheetDevice

    Also called Manuka honey alginate

    Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval

  • JelonetDevice

    Also called paraffin tulle

    Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval

Study groups in NCT02577900
Study groupRoleWhat they receive
Acticoat absorbentExperimentalApply Acticoat absorbent onto the ulcer
Receives: Device: Acticoat absorbent
Honey gel sheetActive comparatorApply Honey gel sheet onto the ulcer
Receives: Device: Honey gel sheet
JelonetOtherApply Jelonet onto the ulcer
Receives: Device: Jelonet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Complete Healing of Ulcer During the Observation Period

    The number of participants have absence of a visible wound achieved by complete epithelialization

    Measured: 12 weeks

Secondary outcomes (4)
  1. Change in Ulcer Size

    Measured: 12 weeks

  2. the Change in Concentration of Matrix Metalloproteinases-9 (MMP-9) Level Inside Wound Fluid at Week 1 and Week 4

    Measured: Week 1, Week 4

  3. the Change in Concentration of Tumor Necrosis Factor Alpha (TNF-α) Level Inside Wound Fluid at Week 1 and Week 4

    Measured: Week 1, Week 4

  4. the Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4

    Measured: Week 1, Week 4

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Oct 2015 (estimated)
  2. Study startFeb 2013
  3. Primary completionAug 2015
  4. Study completionAug 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
31 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02577900
Sponsor's protocol ID
QEH-O&T-001
Acronym
DFU
Status last verified
Apr 2019
First submitted
11 Oct 2015
Last updated
16 Apr 2019
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Acticoat absorbent, Honey gel sheet and Jelonet in people with Diabetic Foot, run by Queen Elizabeth Hospital, Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Jan 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Complete Healing of Ulcer During the Observation Period (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in